The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2020 | Phase I study of AMG-330: a BiTe for R/R AML patients
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses early results of a Phase I dose-escalation study (NCT02520427) exploring the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AMG330, a bi-specific T-cell engager, in patients with relapsed and refractory (R/R) acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
